ProCE Banner Activity

Phase I/II Study of BCMA x CD3 Bispecific Antibody REGN5458 in R/R MM: Updated Safety and Efficacy Results

Slideset Download
Conference Coverage
Updated results from a first-in-human study of REGN5458, a BCMA x CD3 bispecific, shows early, deep, and durable responses in patients with heavily pretreated R/R MM.

Released: December 17, 2021

Expiration: December 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation